title: Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations.
abstract: Substantial evidence has accumulated in support of the hypothesis that elevated cholesterol levels increase the risk of developing Alzheimer disease (AD). As a result, much work has investigated the potential use of lipid-lowering agents, particularly statins, as preventive or therapeutic agents for AD. Although epidemiology and preclinical statin research (described in part I of this review) have generally supported an adverse role of high cholesterol levels regarding AD, human studies of statins (reviewed herein) show highly variable outcomes, making it difficult to draw firm conclusions. We identify several confounding factors among the human studies, including differing blood-brain barrier permeabilities among statins, the stage in AD at which statins were administered, and the drugs' pleiotropic metabolic effects, all of which contribute to the substantial variability observed to date. We recommend that future human studies of this important therapeutic topic (1) take the blood-brain barrier permeabilities of statins into account when analyzing results, (2) include specific analyses of the effects on low- and high-density lipoprotein cholesterol, and, most important, (3) conduct statin treatment trials solely in patients with mild AD, who have the best chance for disease modification.
authors.affiliation: Center for Neurologic Diseases, Department of Neurology, Brigham and Women's Hospital and Harvard Medical School, HIM Room 730, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.
authors.forename: Nina E
authors.initials: NE
authors.lastname: Shepardson
authors.forename: Ganesh M
authors.initials: GM
authors.lastname: Shankar
authors.forename: Dennis J
authors.initials: DJ
authors.lastname: Selkoe
mesh_terms: D000818:Animals; D001812:Blood-Brain Barrier / Q000187:drug effects / Q000378:metabolism; D002784:Cholesterol / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000097:blood / Q000627:therapeutic use*; D006937:Hypercholesterolemia / Q000097:blood* / Q000188:drug therapy* / Q000201:enzymology; D017410:Practice Guidelines as Topic / Q000592:standards*; D016032:Randomized Controlled Trials as Topic / Q000379:methods*
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D002784:Cholesterol
references.citation: Hypertension. 2001 Jun;37(6):1450-7
references.pmid: 11408394
references.citation: Arch Neurol. 2002 Mar;59(3):378-84
references.pmid: 11890840
references.citation: Arch Neurol. 2009 Mar;66(3):343-8
references.pmid: 19273753
references.citation: J Neurol Neurosurg Psychiatry. 2009 Jan;80(1):13-7
references.pmid: 18931004
references.citation: Arch Neurol. 2000 Oct;57(10):1439-43
references.pmid: 11030795
references.citation: J Pharmacol Exp Ther. 1993 Dec;267(3):1085-90
references.pmid: 8263769
references.citation: Dement Geriatr Cogn Disord. 2008;25(3):232-7
references.pmid: 18264008
references.citation: Lancet. 2002 Nov 23;360(9346):1623-30
references.pmid: 12457784
references.citation: Pharm Res. 1994 Feb;11(2):305-11
references.pmid: 8165193
references.citation: Neurology. 2005 May 24;64(10):1689-95
references.pmid: 15911792
references.citation: Neuroepidemiology. 1998;17(1):14-20
references.pmid: 9549720
references.citation: Neurology. 2008 Jul 29;71(5):344-50
references.pmid: 18663180
references.citation: Arch Gen Psychiatry. 2005 Feb;62(2):217-24
references.pmid: 15699299
references.citation: J Neurol Sci. 2009 Aug 15;283(1-2):230-4
references.pmid: 19321181
references.citation: Neurology. 2007 Aug 28;69(9):878-85
references.pmid: 17724290
references.citation: Arch Neurol. 2002 Feb;59(2):223-7
references.pmid: 11843693
references.citation: Arch Neurol. 2005 May;62(5):753-7
references.pmid: 15883262
references.citation: Neurology. 2005 Jan 25;64(2):277-81
references.pmid: 15668425
references.citation: Brain Res. 2002 Jun 28;942(1-2):23-30
references.pmid: 12031849
references.citation: Trends Pharmacol Sci. 1998 Jan;19(1):26-37
references.pmid: 9509899
references.citation: J Neurol Neurosurg Psychiatry. 2005 Dec;76(12):1624-9
references.pmid: 16291883
references.citation: Neurology. 2007 Mar 6;68(10):751-6
references.pmid: 17339582
references.citation: BMC Med. 2007 Jul 19;5:20
references.pmid: 17640385
references.citation: Lancet. 2000 Nov 11;356(9242):1627-31
references.pmid: 11089820
references.citation: Arch Neurol. 2005 Jul;62(7):1047-51
references.pmid: 16009757
references.citation: Ann Neurol. 2010 Jan;67(1):122-31
references.pmid: 20186853
references.citation: J Alzheimers Dis. 2010;22(3):959-70
references.pmid: 20858958
references.citation: Eur J Neurosci. 2003 Jan;17(1):93-102
references.pmid: 12534972
references.citation: J Biol Chem. 2007 Sep 14;282(37):26832-26844
references.pmid: 17646164
references.citation: Neurology. 2010 Mar 23;74(12):956-64
references.pmid: 20200346
references.citation: J Biol Chem. 2005 May 13;280(19):18755-70
references.pmid: 15718241
references.citation: Neurology. 2008 May 6;70(19 Pt 2):1795-802
references.pmid: 18199831
references.citation: Neurology. 2005 Apr 26;64(8):1378-83
references.pmid: 15851727
references.citation: Drug Metab Dispos. 2002 Nov;30(11):1158-63
references.pmid: 12386119
references.citation: Ann Intern Med. 2002 Aug 6;137(3):149-55
references.pmid: 12160362
references.citation: J Pharmacol Exp Ther. 2005 Feb;312(2):786-93
references.pmid: 15358814
references.citation: Int J Neuropsychopharmacol. 2001 Jun;4(2):127-30
references.pmid: 11466161
references.citation: Arch Neurol. 2004 May;61(5):705-14
references.pmid: 15148148
references.citation: Metabolism. 1993 Jul;42(7):895-901
references.pmid: 8345800
references.citation: N Engl J Med. 1999 Aug 12;341(7):498-511
references.pmid: 10441607
references.citation: J Pharm Sci. 1991 Sep;80(9):830-4
references.pmid: 1800703
references.citation: J Cardiovasc Pharmacol. 1993 Feb;21(2):339-46
references.pmid: 7679171